Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin-Reference-Cited by-同舟云学术

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin

Published:2007-04 Issue:4 Volume:55 Page:310-317
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Zuccaro Piergiorgio,Mombelli Giuliana,Calabresi Laura,Baldassarre Damiano,Palmi Ilaria,Sirtori Cesare R.

Publisher

Elsevier BV

Subject

Pharmacology

Reference50 articles.

1. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis;Law;BMJ,2003

2. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins;Baigent;Lancet,2005

3. HMG-CoA reductase inhibitors and myotoxicity;Ucar;Drug Saf,2000

4. Comparative tolerability of the HMG-CoA reductase inhibitors;Farmer;Drug Saf,2000

5. The issue of statin safety. Where do we stand?;Grundy;Circulation,2005

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Determinants of Response to Statins in Cardiovascular Diseases;Current Cardiology Reviews;2024-03

2. When the same treatment has different response: The role of pharmacogenomics in statin therapy;Biomedicine & Pharmacotherapy;2024-01

3. Stroke Pharmacogenetics;Stroke Genetics;2024

4. Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis;Pharmacogenomics;2023-06

5. Genetik und Epigenetik des Alterns;Präventionsmedizin und Anti-Aging-Medizin;2022